Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

The article highlights that XLV’s broad healthcare exposure is diluted versus a pure-play GLP-1 obesity trade: Lilly is only ~16% of XLV versus ~16.10% in OZEM, while Novo is ~13.13% in OZEM; together GLP-1-dominant makers are 29.23% of OZEM vs a much smaller thematic concentration in XLV. It cites Lilly’s Q1 2026 strength—revenue $19.8B (+55.5% YoY), Mounjaro $8.66B (+125%) and Zepbound $4.16B (+80%)—and notes OZEM returned 32.8% over the past year vs XLV’s 21.61% but lags Lilly’s 54.8%, with OZEM also showing YTD -1.18% while XLV is +5.51%. Net: thematic exposure can improve upside capture, but OZEM’s small $51.4M AUM, ~12.89% cash position, and small-cap biotech volatility add performance drag and operational/closure risk.

Analysis

This is less a sector call than a vehicle-selection trade. If the market is really buying the obesity franchise, the cleanest economic exposure is still LLY: it owns the operating leverage, pricing power, and the closest path to broadening the addressable market as oral adoption lowers friction over the next 6-18 months. By contrast, XLV behaves like a low-beta wrapper that will under-capture the theme unless obesity names continue to dominate healthcare leadership; the dilution matters most when the market rotates away from megacap growth and back into diversified defensives.

Second-order effects favor a narrow basket of adjacencies, but only if the launch curve is real. VKTX, GPCR, and ZLDPF can re-rate on partnership/M&A optionality if management teams prove they can remain relevant in an oral-first market; otherwise they are just duration-sensitive biotech names with financing risk. NVO is the obvious relative loser until it demonstrates a cleaner U.S. execution path, because the bar for multiple expansion is now higher after a period of underperformance and pricing pressure.

The contrarian point is that OZEM may look like the “pure” obesity trade but is structurally handicapped by concentration, cash drag, and liquidity; if flows do not accelerate, the wrapper can lag even in a good thematic tape. The better 1-3 month catalyst path is likely relative performance rather than absolute returns: LLY versus NVO, or LLY versus XLV. The main falsifier is a failure of obesity script growth or any disappointment in oral GLP-1 commercialization, which would compress the premium multiple quickly over 1-2 quarters.

Key Decisions for Investors

• Long LLY vs short NVO for 3-6 months: best risk/reward if the market keeps rewarding the oral GLP-1 adoption story; thesis breaks if NVO shows a credible regain in U.S. share or if LLY guidance implies slower-than-expected commercialization.
• Overweight LLY relative to XLV rather than adding OZEM: cleaner exposure with less cash drag and no closure/liquidity overhang; use XLV as a defensive core only if the goal is broad healthcare beta.
• Avoid buying OZEM aggressively at market; if used at all, make it a small sleeve on pullbacks with limit orders given wider spreads and small AUM risk. Falsifier: persistent underperformance versus XLV despite continued obesity sector strength.
• Watch VKTX/GPCR/ZLDPF for event-driven upside only on financing/partnership headlines; otherwise do not chase them as standalone longs. Best use is a small basket against a short in a broader biotech ETF if obesity enthusiasm broadens into speculative small-cap multiples.
• Set an alert on LLY/NVO relative strength and GLP-1 script data over the next 1-2 quarters; if LLY starts to stall while XLV stays firm, rotate back toward the diversified sector basket.